NSCLC (following checkpoint inhibitors; combo with docetaxel) | XPORT-NSCLC-039
Indication: NSCLC
Title: Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)
Drug: Selinexor
Please visit clinicaltrials.gov for more information about this study
This trial is for selinexor.
Early Stage | Mid Stage | Late Stage | Commercial |
---|---|---|---|
Early Stage | Mid Stage | Late Stage | Commercial |